1. Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma.
- Author
-
Nakano M, Sogawa CA, Sogawa N, Mishima K, Yamachika E, Mizukawa N, Fukunaga J, Kawamoto T, Sawaki K, Sugahara T, and Furuta H
- Subjects
- Carcinoma, Squamous Cell genetics, Drug Screening Assays, Antitumor, Humans, Metallothionein genetics, Protein Isoforms biosynthesis, Protein Isoforms genetics, RNA, Messenger biosynthesis, RNA, Messenger genetics, Reverse Transcriptase Polymerase Chain Reaction, Tongue Neoplasms genetics, Tumor Cells, Cultured, Antineoplastic Agents pharmacology, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell metabolism, Cisplatin pharmacology, Metallothionein biosynthesis, Tongue Neoplasms drug therapy, Tongue Neoplasms metabolism
- Abstract
Cisplatin (CDDP) is a useful drug for the treatment of malignant solid tumors of the head and neck. Because CDDP includes the heavy metal platinum as a component, it is thought metallothionein (MT) may be involved in CDDP-resistance. However, functional differences between the four MT isoforms (MT-I, II, III and IV) remain unclear. The aim of this study was to investigate the relationship between MT isoform expression and CDDP-resistance. Two human tongue squamous cell carcinoma cell lines not exposed to anticancer chemotherapy were studied. The cell lines were subjected to reverse transcriptase-polymerase chain reaction (RT-PCR) analysis before and after CDDP-treatment. Both cell lines expressed MT-I/II and MT-IV isoforms but not the MT-III isoform. Following CDDP treatment, MT-I/II mRNA levels were induced only in the CDDP-resistant cell line. Our results showed that expression of the MT I/II isoform was induced by CDDP treatment, and may play an important role in CDDP-resistance in squamous cell carcinoma of the human tongue.
- Published
- 2003